OutPerformDaily

  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks

Lost Password?

Top 3 AI Stocks to Invest in Right Now

Fake shopping sprees and ‘happiness insurance’: The latest fintech apps reveal our financial anxieties

Is Apple’s foldable iPhone Duo worth $2,000? See how it stacks up against other foldable phones.

I gave my HomeExchange guest a 5-star review. Then I found heat marks all over my dining table. Do I call her out?

Inside the push to weaken Washington’s toughest financial watchdog

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
3rdPartyFeeds

PayPal price target raised to $86 from $82 at BofA

October 31, 2024

BofA raised the firm’s price target on PayPal (PYPL) to $86 from $82 and keeps a Neutral rating on the shares. The firm is “not surprised” to see PayPal...

3rdPartyFeeds

Dow Jones Futures Fall As Microsoft, Meta Slide On Guidance; Robinhood Dives

October 31, 2024

Microsoft and Meta topped views late, though their stocks diverged. Robinhood and two bitcoin plays sold off. Read More...

3rdPartyFeeds

Snap price target raised to $13 from $12 at UBS

October 31, 2024

UBS raised the firm’s price target on Snap (SNAP) to $13 from $12 and keeps a Neutral rating on the shares. Snap’s Q3 revenue was in-line and Q4 guidance was...

3rdPartyFeeds

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

October 31, 2024

The pharmaceutical giant also raised its full-year revenue forecast to an increase of more than 5%. Read more...

3rdPartyFeeds

Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall

October 31, 2024

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.  Read more...

3rdPartyFeeds

Stock Futures Diving as Microsoft, Meta Earnings Spook Markets Amid Super Micro Selloff

October 31, 2024

Big Tech earnings are spooking investors. The market may have expected another treat following Microsoft and Meta’s earnings late Wednesday, particularly after...

3rdPartyFeeds

Billionaire Philippe Laffont of Coatue Is Dumping Shares of Nvidia and Palantir and Piling Into This Artificial Intelligence (AI) Infrastructure Juggernaut

October 31, 2024

Laffont's Coatue Management sent shares of Wall Street's two hottest artificial intelligence (AI) stocks packing in the June-ended quarter in favor of a...

3rdPartyFeeds

Microsoft results top estimates but AI capacity constraints remain; stock down

October 31, 2024

Microsoft (NASDAQ:MSFT) reported fiscal first-quarter results that topped Wall Street estimates, underpinned by strength at its cloud unit, shares in the...

3rdPartyFeeds

1 Spectacular BlackRock ETF to Buy Ahead of the Russell 2000 Bull Market

October 31, 2024

Many small-cap stocks have delivered solid returns in 2024, but the benchmark Russell 2000 index is still trading in bear territory. Read More...

3rdPartyFeeds

Dodge maker Stellantis posts 27% drop in revenues, flags progress in slashing U.S. inventories

October 31, 2024

Auto giant Stellantis on Thursday reported a 27% decline in third-quarter revenues, but said it was making headway in addressing operational issues like U.S...

Previous 1 … 444 445 446 447 448 … 8,455 Next
Indices by TradingView

Categories

  • 3rdPartyFeeds
  • Cannabis Stocks
  • Index Funds
  • International
  • News
  • Short
  • Stock Picks
  • Tech Stocks
  • Uncategorized
Indices by TradingView
While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.